The Companion Diagnostics for Oncology Market is scaling as precision medicine moves to biomarker-guided therapeutic decisions, reshaping oncology treatment and personalized care. Leading pharma companies and cancer centers are embedding tissue-based and liquid biopsy CDx tests across clinical workflows. Market valued at USD 12.5B in 2024, projected USD 52B by 2035, CAGR 14.2% .

Three domains scale rapidly: oncology CDx with EGFR/ALK/PD-L1 testing for targeted therapy; pharmacogenomics CDx for drug metabolism prediction; and emerging therapeutic areas with biomarker discovery. This positions the market for growth through 2035 .

Browse Details of [FURL=https://www.marketresearchfuture.com/reports/companion-diagnostics-oncology-market-10422Companion Diagnostics for Oncology Market[/FURL] Research Report

Leaders include pharma (Roche, AstraZeneca) and diagnostic companies (Foundation Medicine, Guardant Health) with co-development partnerships. Investments in NGS panels and liquid biopsy enable scaling while maintaining FDA/EMA compliance.

Key trends include multi-gene NGS panels replacing single-gene tests, liquid biopsy CDx for monitoring, AI-powered biomarker discovery, tumor-agnostic biomarkers (NTRK, MSI-H), and EHR integration. FDA/CMS clarity, nearly 50% of new oncology approvals requiring CDx, and improved outcome evidence support expansion .

Other Related MRFR Insights in Healthcare Industry

Germany Anesthesia Breathing Circuits Market

India Anesthesia Breathing Circuits Market

Italy Anesthesia Breathing Circuits Market

Japan Anesthesia Breathing Circuits Market

South America Anesthesia Breathing Circuits Market

South Korea Anesthesia Breathing Circuits Market